By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Apthera, Inc. (Acquired by RXi Pharmaceuticals) 

Press releases archived for reference only.
14861 N. Scottsdale Road, Suite 201
Scottsdale  Arizona  85254  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
RXi Pharmaceuticals (RXII) Completes Apthera, Inc. Acquisition 4/14/2011 1:36:03 PM
Apthera, Inc. and RXi Pharmaceuticals (RXII) Announce Definitive Merger Agreement Valued at $7.2 Million, Names New CEO 3/31/2011 6:53:51 AM
Dr. Mark W. Schwartz Joins Apthera, Inc. as President & CEO 1/8/2010 7:04:05 AM
Investment Banking Executive Ira Z. Leiderman and Dr. Mary Ann Gray Join the Board of Directors at Apthera, Inc. 10/9/2009 8:22:02 AM
Apthera, Inc. Receives Special Protocol Assessment (SPA) From FDA for Pivotal Phase III Trial of NeuVax in Early-Stage Breast Cancer 6/25/2009 10:10:34 AM
Apthera, Inc. Announces Product License Agreement With Kwang Dong Pharmaceutical 6/4/2009 11:28:45 AM
Apthera, Inc. Announces Phase III and Commercial Drug Formulation for NeuVax(TM) 12/9/2008 8:33:18 AM
Apthera, Inc. Announces Optimal Dose And Schedule Of Neuvax For Phase III Clinical Trial In Breast Cancer 10/1/2008 10:01:45 AM
Apthera, Inc. and TGen Drug Development Services (TD2) Sign Master Services Agreement 8/5/2008 9:09:59 AM
Apthera, Inc.'s NeuVax™ Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients 6/2/2008 11:35:25 AM